Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
5(71.4%)
Phase 1
2(28.6%)
7Total
Phase 2(5)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT01135108Phase 2Completed

Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Spinal Cord Injury

Role: collaborator

NCT01106716Phase 2Completed

Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia

Role: collaborator

NCT01052142Phase 1Completed

Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma

Role: collaborator

NCT01015235Phase 2Completed

Safety and Efficacy Study of KAI-1678 to Treat Subjects With Postoperative Pain

Role: collaborator

NCT01055002Phase 1Completed

A Pilot Study to Test Activity of Antimalarial Drugs Against an Induced Malaria Infection in Healthy Volunteers

Role: collaborator

NCT00854685Phase 2Completed

Dose Optimisation Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate

Role: collaborator

NCT00468247Phase 2Completed

Registration Enabling Study of the Safety and Efficacy of the Use of the Navigator Circulatory Management System

Role: collaborator

All 7 trials loaded